Association between toll-like receptor polymorphisms and serum levels of tumor necrosis factor-α and its soluble receptors in obese children

Medical Science Monitor

Volumn 16, Issue 4, 2010, Pages

  Jermendy, Agnes ^a   Körner, Anna ^a   Kovács, Margit ^b   Kaszás, Edit ^c   Balázsovics, Judit ^c   Szocs, Albert ^c   Madácsy, László ^a   Cseh, Károly ^c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c Karolyi Hospital   (Hungary)

Author keywords

Children; Insulin resistance; Obesity; TNF ; Toll like receptor 4

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; CYTOKINE; TLR2 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR;

ADOLESCENT; ARTICLE; CARDIOVASCULAR RISK; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DNA EXTRACTION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; HETEROZYGOTE DETECTION; HUMAN; HYPERTENSION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; ALLELE; BLOOD; BODY MASS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC POLYMORPHISM; GENETICS; INSULIN RESISTANCE; METABOLISM; METHODOLOGY;

ADOLESCENT; ALLELES; BODY MASS INDEX; CHILD; CROSS-SECTIONAL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; OBESITY; POLYMORPHISM, GENETIC; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954301798     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Weiss R, Dziura J, Burgert TS et al: Obesity and the metabolic syndrome in children and adolescents. N Engl J Med, 2004; 350: 2362-74
2. Dietz WH: Childhood weight affects adult morbidity and mortality. J Nutr, 1998; 128: 411S-14S
3. Weiss R, Kaufman FR: Metabolic complications of childhood obesity. Identifying and mitigating the risk. Diabetes Care, 2008; 31(Suppl.2): S310-16
4. Kamath CC, Vickers KS, Ehrlich A et al: Clinical review: behavioral interventions to prevent childhood obesity: a systematic review and metaanalyses of randomized trials. J Clin Endocrinol Metab, 2008; 93: 4606-15
5. Caprio S: Insulin resistance in childhood obesity. J Pediatr Endocrinol Metab, 2002; 15(Suppl.l): 487-92
6. Beltowski J: Adiponectin and resistin - new hormones of white adipose tissue. Med Sci Monit, 2003; 9(2): RA55-61
7. Beltowsky J: Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity? Med Sci Monit, 2006; 12(6): RA112-19
8. Nisoli E, Briscini L, Giordano A et al: Tumor necrosis factor alpha mediates apoptosis of brown adipocytes and defective brown adipocyte function in obesity. Proc Natl Acad Sci USA, 2000; 97: 8033-38
9. Kanety H, Feinstein R, Papa MZ et al: Tumor necrosis alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem, 1995; 270: 23780-84
10. Hotamisligil GS, Peraldi P, Budavari A et al: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesityinduced insulin resistance. Science, 1996; 271: 665-68
11. Hotamisligil GS, Arner P, Caro JF et al: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest, 1995; 95: 2409-15
12. Fernandez-Real J-M, Broch M, Ricart W et al: Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes, 1998; 47: 1757-62
13. Hauner H, Bender M, Haastert B, Hube F: Plasma concentration of soluble TNF-alpha receptors in obese subjects. Int J Obes Relat Metab Disord, 1998; 22: 1239-43
14. Tsukumo DML, Carvalho-Filho MA, Carvalheira JBC et al: Loss-offunction mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes, 2007; 56: 1986-98
15. Radin MS, Sinha S, Bhatt BA et al: Inhibition or deletion of the lipopolysaccharide receptor Toll-like receptor-4 confers partial protection against lipid-induced insulin resistance in rodent skeletal muscle. Diabetologia, 2008; 51: 336-46
16. Kim JK: Fat uses a TOLL-road to connect inflammation and diabetes. Cell Metab, 2006; 4: 417-19
17. Shi H, Kokoeva MV, Inouye K et al: TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest, 2006; 116: 3015-25
18. Arbour NC, Lorenz E, Schutte BC et al: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet, 2000; 25: 187-91
19. Schroder NW, Schumann RR: Single nucleotide polymorphisms of Tolllike receptors and susceptibility to infectious disease. Lancet Infect Dis, 2005; 5: 156-64
20. Lorenz E, Mira JP, Frees KL, Schwartz DA: Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch Intern Med, 2002; 162: 1028-32
21. Lorenz E, Mira JP, Cornish KL et al: A novel polymorphism in the tolllike receptor 2 gene and its potential association with staphylococcal infection. Infect Immun, 2000; 68: 6398-401
22. Ogus AC, Yoldas B, Ozdemir T et al: The Arg753Gln polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. Eur Respir J, 2004; 23: 219-23
23. Hamann L, Gomma A, Schroder NW et al: A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis. J Mol Med, 2005; 83: 478-85
24. Labrum R, Bevan S, Sitzer M et al: Toll receptor polymorphisms and carotid artery intima-media thickness. Stroke, 2007; 38: 1179-84
25. Haag M, Dippenaar NG: Dietary fats, fatty acids and insulin resistance: short review of a multifaceted connection. Med Sci Monit, 2005; 11(12): RA359-67
26. Soergel M, Kirschstein M, Busch C et al: Oscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: a multicenter trial including 1141 subjects. J Pediatr, 1997; 130: 178-84
27. WHO: Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva, 1999
28. Zimmet P, Alberti G, Kaufman F et al: International Diabetes Federation Task Force on Epidemiology and Prevention of Diabetes. The metabolic syndrome in children and adolescents. Lancet, 2007; 369: 2059-61
29. Lorenz E, Frees KL, Schwartz DA: Determination of the TLR4 genotype using allele-specific PCR. Biotechniques, 2001; 31: 22-24
30. Schmitt C, Humeny A, Becker CN et al: Polymorphisms of TLR4: Rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles. Clin Chem, 2002; 48: 1661-67
31. Yoon HJ, Choi JY, Kim CC et al: Lack of Toll-like receptor 4 and 2 polymorphisms in Korean patients with bacteremia. J Korean Med Sci, 2006; 21: 979-82
32. Dzienis-Straczkowska S, Straczkowski M, Szelachowska M et al: Soluble tumor necrosis factor-alpha receptors in young obese subjects with normal and impaired glucose tolerance. Diabetes Care, 2003; 26: 875-80
33. Plomgaard P, Nielsen AR, Fischer CP et al: Associations between insulin resistance and TNA-alpha in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes. Diabetologia, 2007; 50: 2562-71
34. Gupta A, Ten S, Anhalt H: Serum levels of soluble tumor necrosis factor-alpha receptor 2 are linked to insulin resistance and glucose intolerance in children. J Pediatr Endocrinol Metab, 2005; 18: 75-82
35. Shai I, Schulze MB, Manson JE et al: A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes. Diabetes Care, 2005; 28: 1376-82
36. Cseh K, Winkler G, Merlczer Z, Baranyi E: The role of tumour necrosis factor (TNF)-alpha resistance in obesity and insulin resistance (Letter). Diabetologia, 2000; 43: 525
37. Kiechl S, Lorenz E, Reindl M et al: Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med, 2002; 347: 185-92
38. Boekholdt SM, Agema WR, Peters RJ et al, Regression Growth Evaluation Statin Study Group: Variants of Toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation, 2003; 107: 2416-21
39. Enquobahrie DA, Smith NL, Bis JC et al: Cholesterol ester transfer protein, interleukin-8, peroxisome proliferator activator receptor alpha, and Toll-like receptor 4 genetic variations and risk of incident nonfatal myocardial infarction and ischemic stroke. Am J Cardiol, 2008; 101: 1683-88
40. Morange PE, Tiret L, Saut N et al, PRIME Study Group: TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study. Eur J Hum Genet, 2004; 12: 1041-49
41. Norata GD, Garlaschelli K, Ongari M et al: Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. J Intern Med, 2005; 258: 21-27
42. Reismann P, Lichy C, Rudofsky G et al: Lack of association between polymorphisms of the Toll-like receptor 4 gene and cerebral ischemia. J Neurol, 2004; 251: 853-58
43. Reyna SM, Ghosh S, Tantiwong P et al: Elevated Toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes, 2008; 57: 2595-602
44. Poggi M, Bastelica D, Gual P et al: C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia, 2007; 50: 1267-76